Prostate, page-63

Just one from last century
braeckman, et al, 1997

Abstract : Efficacy and safety of the extract of Serenoa repens in the treatment of benign prostatic hyperplasia: therapeutic equivalence between twice and once daily dosage forms

The efficacy and safety of two dosage forms (160 mg b.i.d. and 320 mg o.d.) of the extract of Serenoa repens were compared during a 1-year treatment in 132 patients suffering from benign prostatic hyperplasia (BPH). Both dosage forms induced a significant improvement in the efficacy variables: international prostate symptom score (60% after 1 year), quality of life score (85% of patients were satisfied after 1 year of treatment), prostatic volume (12% after 1 year), maximum flow rate (22% after 1 year), mean flow rate (17% after 1 year) and residual urinary volume (16% after 1 year). No significant differences were found between the two dosage forms. The percentage of patients or investigators evaluating that the treatment had a medium or bad tolerance was never superior to 4%. Nineteen side effects were observed in 16 patients (12.1%), 8 patients in each group. The majority of these side effects (at least 75%) were related to the natural evolution of the disease itself rather than to the medication. We conclude that the extract of Serenoa repens in its two dosage forms is a safe and effective treatment for the mictional problems associated with BPH. Consequently, it appears to offer a potential pharmacologic alternative capable of improving BPH symptoms in patients with mild-to-moderate disease. © 1997 John Wiley & Sons, Ltd.
Source: http://onlinelibrary.wiley.com/doi/...9712)11:8<558::AID-PTR158>3.0.CO;2-U/abstract